A Study Comparing the Efficacy of TCbHP and ECHP-THP in the Neoadjuvant Treatment of HER2-positive Breast Cancer

PHASE3

Phase

WITHDRAWN

Status

OTHER_GOV

Sponsor class

Stopped The new treatment plan for HER2 positive breast cancer has entered the diagnosis and treatment guide. The treatment plan ECHP-THP in this study is not the optimal treatment plan, therefore this study was terminated.

Conditions

Breast Cancer
HER2-positive Breast Cancer

Interventions

DRUG: Docetaxel + Carboplatin + Trastuzumab + Pertuzumab
DRUG: (Epirubicin + Cyclophosphamide - Docetaxel) + (Trastuzumab + Pertuzumab)

Sponsor

Henan Cancer Hospital